Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 20:13:885144.
doi: 10.3389/fimmu.2022.885144. eCollection 2022.

E Protein Transcription Factors as Suppressors of T Lymphocyte Acute Lymphoblastic Leukemia

Affiliations
Review

E Protein Transcription Factors as Suppressors of T Lymphocyte Acute Lymphoblastic Leukemia

Geoffrey Parriott et al. Front Immunol. .

Abstract

T Lymphocyte Acute Lymphoblastic Leukemia (ALL) is an aggressive disease arising from transformation of T lymphocytes during their development. The mutation spectrum of T-ALL has revealed critical regulators of the growth and differentiation of normal and leukemic T lymphocytes. Approximately, 60% of T-ALLs show aberrant expression of the hematopoietic stem cell-associated helix-loop-helix transcription factors TAL1 and LYL1. TAL1 and LYL1 function in multiprotein complexes that regulate gene expression in T-ALL but they also antagonize the function of the E protein homodimers that are critical regulators of T cell development. Mice lacking E2A, or ectopically expressing TAL1, LYL1, or other inhibitors of E protein function in T cell progenitors, also succumb to an aggressive T-ALL-like disease highlighting that E proteins promote T cell development and suppress leukemogenesis. In this review, we discuss the role of E2A in T cell development and how alterations in E protein function underlie leukemogenesis. We focus on the role of TAL1 and LYL1 and the genes that are dysregulated in E2a-/- T cell progenitors that contribute to human T-ALL. These studies reveal novel mechanisms of transformation and provide insights into potential therapeutic targets for intervention in this disease.

Keywords: E protein; LYL1; Leukemia; T lymphocyte; TAL1; murine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of T cell development in WT and E2a-/- mice. T cell development in WT mice is depicted in the top half of the figure. Tal1:E2A (or E protein) dimers are prevalent in HSCs and decline as progenitors differentiate toward the T cell lineage. At the time of thymic commitment E2a:HEB dimers dominate. NOTCH1 and GATA3 start to be expressed upon thymic entry, along with TCF1 (not depicted) under the influence of NOTCH1 ligands in the thymus. LEF1 expression initiates with commitment to the T lymphocyte lineage but remains low throughout T cell development. T cell development in E2a-/- mice is depicted on the lower half of the figure. Here, Tal1:HEB or E2-2 dimers control early hematopoiesis resulting in a reduced number of thymic seeding progenitors that can only express HEB : HEB or E2-2 dimers after extinction of TAL1 expression. GATA3 expression is high and diverts progenitors toward the ILC/NK fate. Mutations in the Notch1 gene accumulate and LEF1 is expressed at very high levels. Combined, these alterations in NOTCH1, GATA3 and LEF1 contribute to T cell transformation.
Figure 2
Figure 2
The TAL1 genomic locus and mutations leading to ectopic expression in T lymphocytes and T-ALL. The WT TAL1 locus is depicted downstream of the STIL gene. TAL1 transcription is increased in T lymphocytes through genomic translocation into the TCRB/A/D locus, through genomic deletions bringing the STIL enhancer close to TAL1 or through insertions that create a novel MYB binding enhancer upstream of TAL1.

Similar articles

Cited by

References

    1. Belver L, Ferrando A. The Genetics and Mechanisms of T Cell Acute Lymphoblastic Leukaemia. Nat Rev Cancer (2016) 16(8):494–507. doi: 10.1038/nrc.2016.63 - DOI - PubMed
    1. Ferrando AA, Look AT. Gene Expression Profiling in T-Cell Acute Lymphoblastic Leukemia. Semin Hematol (2003) 40(4):274–80. doi: 10.1016/s0037-1963(03)00195-1 - DOI - PubMed
    1. Noronha EP, Marques LVC, Andrade FG, Thuler LCS, Terra-Granado E, Pombo-de-Oliveira MS, et al. . The Profile of Immunophenotype and Genotype Aberrations in Subsets of Pediatric T-Cell Acute Lymphoblastic Leukemia. Front Oncol (2019) 9:316. doi: 10.3389/fonc.2019.00316 - DOI - PMC - PubMed
    1. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. . Early T-Cell Precursor Leukaemia: A Subtype of Very High-Risk Acute Lymphoblastic Leukaemia. Lancet Oncol (2009) 10(2):147–56. doi: 10.1016/S1470-2045(08)70314-0 - DOI - PMC - PubMed
    1. Van Vlierberghe P, Ferrando A. The Molecular Basis of T Cell Acute Lymphoblastic Leukemia. J Clin Invest (2012) 122(10):3398–406. doi: 10.1172/JCI61269 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources